Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Peripheral nerve conduction block
What ifWhat if an injected local anesthetic controls pain by blocking conduction in a peripheral nerve?
Claim language“an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1)”
A clinician uses ultrasound to guide injection of a local anesthetic next to the nerve supplying the painful region. The anesthetic blocks voltage-gated sodium channels and interrupts action potential propagation along the nerve.
1.1Topical prostaglandin suppression
What ifWhat if a topical anti-inflammatory gel reduces pain by suppressing prostaglandin production near a painful joint?
Claim language“an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1)”
The patient applies a gel containing a nonsteroidal anti-inflammatory drug to the skin over the affected joint. The drug inhibits local cyclooxygenase activity and lowers production of prostaglandins that sensitize peripheral nociceptors.
1.1Spinal calcium channel modulation
What ifWhat if an oral drug reduces neuropathic pain by binding an auxiliary subunit of voltage-gated calcium channels?
Claim language“an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1)”
The drug binds the alpha-2-delta subunit on neurons involved in spinal pain transmission. This reduces excitatory neurotransmitter release from presynaptic terminals in the dorsal horn.
1.1Electrical stimulation through skin
What ifWhat if electrical pulses delivered through skin electrodes reduce pain?
Claim language“an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1)”
A battery-powered pulse generator drives a pair of adhesive electrodes placed around the painful region. At a comfortable sensory intensity, the pulses recruit large-diameter sensory fibers whose input reduces nociceptive transmission in the spinal dorsal horn.
1.1Topical nociceptor desensitization
What ifWhat if a topical patch reduces localized neuropathic pain through sustained activation of heat-sensitive receptors?
Claim language“an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1)”
A clinician applies a patch containing a TRPV1 agonist over the painful skin. Sustained receptor activation makes the exposed cutaneous nociceptor endings temporarily less responsive to stimulation.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Veterinary joint pain study
A veterinary osteoarthritis study uses a sterile suspension of an ERO1 inhibitor in a carrier selected for intra-articular delivery. The suspension is injected into the affected joint, and an instrumented walkway records limb loading before and after administration. A carrier-only group follows the same schedule, and the study compares each animal’s change in weight bearing from baseline.
Component substitution
Small interfering RNA against ERO1A
A small interfering RNA duplex targeting ERO1A messenger RNA replaces the small-molecule inhibitor. A lipid transfection reagent delivers the duplex to cultured sensory neurons, where RNA interference reduces ERO1A expression. A parallel culture receives a nontargeting duplex, and immunoblotting and patch-clamp recordings measure ERO1A abundance and the current required to trigger an action potential.
Parameter or scale variation
Concentration and exposure time matrix
A multiwell sensory-neuron culture receives an ERO1 inhibitor at 0.1, 0.3, 1, 3, and 10 micromolar, with the same solvent fraction in every well. Separate well sets receive the inhibitor for 30 minutes or 24 hours, and each set includes solvent-only controls. At each endpoint, calcium imaging records responses to a fixed depolarizing stimulus, and a viability assay measures cell survival in matched wells.
Combination with existing systems
Spinal delivery with an infusion pump
A programmable infusion pump connects through a sterile line to an intrathecal catheter in a preclinical pain model. The reservoir contains a sterile solution of a water-soluble ERO1 inhibitor, and the pump meters the solution at a preset flow rate. The pump log records delivery times, and the study measures mechanical withdrawal thresholds at fixed times relative to infusion.
Local delivery from a wound hydrogel
A sterile cross-linked polyethylene glycol hydrogel carries a dissolved ERO1 inhibitor in a preclinical incisional pain model. The gel sits over the closed incision beneath a secondary dressing and releases the inhibitor by diffusion into fluid at the wound surface. A parallel group receives an unloaded gel, and measurements track local inhibitor concentration and mechanical sensitivity near the incision.
Automated or data-driven variant
Automated dosing and firing measurements
A robotic liquid handler dispenses an ERO1 inhibitor and matched solvent controls into sensory-neuron cultures on a multiwell microelectrode array. Acquisition software records spontaneous firing before dosing and applies the same electrical pulse sequence to each well after dosing. Analysis software aligns spike trains to each pulse and calculates the change in spontaneous firing rate and the fraction of pulses that elicit spikes.
Specific version of a part
Reduced state enzyme inhibition
A small molecule engages the reduced form of endoplasmic reticulum oxidoreductin 1 and promotes dissociation of its flavin adenine dinucleotide cofactor. Loss of the cofactor decreases enzyme activity and slows reoxidation of protein disulfide isomerase.
Oral suspension of enzyme inhibitor
A liquid formulation disperses micronized particles of a small-molecule oxidoreductin 1 inhibitor in an aqueous vehicle thickened with a cellulose derivative. The suspension is shaken before a measured volume is drawn into an oral syringe.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1administering a therapeutically effected amount an inhibitor of Endoplasmic Reticulum Oxidoreductin 1 (EOR1).
The endoplasmic reticulum stress inhibitor according to the present invention can inhibit endoplasmic reticulum stress in mammalian cells, especially neurons, and can be taken on a long-term basis to provide food, drink, and drugs for prevention, symptom reduction, and improvement of the endoplasmic reticulum stress.
A · US 2024/0415797 A1 · ¶ 20
A method of treating a patient having cancer comprising administering to the patient a therapeutically effective amount of a compound that is a derivative of sulfuretin that are inhibitors of the endoplasmic reticulum oxidoreductin-1 alpha to a patient is disclosed.
B · US 2025/0064773 A1 · abstract
An empty cell means only that no passage was reproduced there.
Statements in these documents
The invention relates to an inhibitor that improves endoplasmic reticulum stress by using a triglyceride composed of saturated fatty acids, mainly pentadecanoic acid.
A · US 2024/0415797 A1 · ¶ 2
These agents can be used in various forms, including food products and pharmaceutical compositions.
A · US 2024/0415797 A1 · ¶ 2
This invention provides for a method of targeting Ero1α for treatment of cancer.
B · US 2025/0064773 A1 · ¶ 3
However, emergence of resistance to targeted and immunotherapies remains a clinical obstacle for increasing overall survival and improving patient outcomes2-5.
B · US 2025/0064773 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355162 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355162/, SHA-256 b714807dfce2b143e5886f3c7f25317dfa36b662236a9835d385f7c37f7b4d97